title: Glucagon-like peptide-1 and-2 levels in children with diabetic ketoacidosis.
abstract: OBJECTIVE
  The aim of this study was to investigate whether insulin deficiency and increased catabolism may have a role in the regulation of plasma glucagon-like peptide (GLP)-1 and GLP-2 levels in children with diabetic ketoacidosis (DKA) and whether insulin treatment may affect the levels of these polypeptides.
  
  
  METHODS
  Plasma GLP-1 and -2 levels were measured in 24 patients with DKA aged 8 to 14 years before insulin infusion (time 0), when ketonemia and acidosis disappeared (time 1), and when weight gain started (time 2). Eighteen healthy children aged 8 to 14 years constituted the control group.
  
  
  RESULTS
  At time 0, mean plasma GLP-1 and GLP-2 levels were significantly elevated in the patients compared with the control group (p<0.05 and p<0.01, respectively). At time 1 when ketonemia and acidosis disappeared, GLP-1 and GLP-2 levels decreased significantly from the initial levels (p<0.05 and p<0.01, respectively). At this time, while GLP-1 level was not different from that of the controls, GLP-2 level was higher than that of the controls (p<0.05). GLP-1 and-2 levels did not show any significant differences between the patients and controls when weight gain started (time 2).
  
  
  CONCLUSIONS
  Our results show that DKA is associated with increased plasma GLP-1 and -2 concentrations. Effective fluid and insulin treatment resulted in a significant decrease in plasma GLP-1 and -2 levels. This may be due to the negative feedback effect of insulin on the production of these polypeptides.
authors.affiliation: Pediatric Endocrinology Department, İnönü University, Turgut Özal Medical Center, Malatya, Turkey. aakinci@inonu.edu.tr
authors.forename: Ayşehan
authors.initials: A
authors.lastname: Akıncı
authors.forename: Özgür
authors.initials: Ö
authors.lastname: Aydın
authors.forename: Halil İbrahim
authors.initials: Hİ
authors.lastname: Özerol
mesh_terms: D000293:Adolescent; D016022:Case-Control Studies; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy; D016883:Diabetic Ketoacidosis / Q000097:blood* / Q000188:drug therapy; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D053767:Glucagon-Like Peptide 2 / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008297:Male
chemical_list: D053767:Glucagon-Like Peptide 2; D007004:Hypoglycemic Agents; D007328:Insulin; D052216:Glucagon-Like Peptide 1